Clinical Trials Logo

Alcohol Drinking clinical trials

View clinical trials related to Alcohol Drinking.

Filter by:

NCT ID: NCT02449577 Completed - Insulin Resistance Clinical Trials

Identification of Biomarkers for Acute Intake of Beer and Alcohol and Acute Effects on Plasma and Insulin Response

METABEER
Start date: May 2013
Phase: Phase 0
Study type: Interventional

The objective of the study is to identify biomarkers for acute intake of beer and alcohol in individuals with a high or low habitual intake. Furthermore, we wish to identify compounds and metabolites in different types of beer and alcohol, which can serve as compliance markers for intake under the test conditions (blood tests and urine samples). We also wish to determine the acute effects of these beverages on plasma glucose and insulin response, compared to regular soda.

NCT ID: NCT02445339 Completed - Clinical trials for Alcohol Use Disorder

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

Start date: July 2015
Phase: Phase 4
Study type: Interventional

Our primary aim is to assess the feasibility of initiating treatment in the ED with extended-release naltrexone (XR-NTX) plus care management (CM) vs. standard care and continuing care in cooperation with clinic providers as well as how best to assess outcomes. Secondarily, the investigators will explore its effect on various health outcomes (healthcare utilization and engagement, expenditures, drinking and consequences, quality of life) as well as the association of patient-level characteristics (e.g. sex, race, baseline drinking, health and psychosocial factors, mu opioid receptor genotype) with effectiveness. Determining both how to implement XR-NTX+CM and rigorously test its effects in the ED (phase 1) is essential before planning a large-scale effectiveness trial (phase 2).

NCT ID: NCT02426957 Completed - Suicide Clinical Trials

Brief Alcohol Intervention for Adolescents Who Have Attempted Suicide

Start date: October 2014
Phase: Phase 1
Study type: Interventional

The study will use a two group randomized controlled trial to compare a brief motivational interviewing (MI) intervention to TAU with 50 adolescents psychiatrically hospitalized for a suicide plan or attempt who have co-occurring alcohol use. Data will be collected via in-person interviews and self-administered questionnaires at baseline and 3 month follow-up assessments to explore outcome changes in negative alcohol expectancies, confidence in ability to handle situations where alcohol is present, likelihood of receiving alcohol treatment, frequency of alcohol use, and suicidal ideation, suicide planning, and suicide attempts for adolescents receiving the intervention relative to TAU.

NCT ID: NCT02390908 Completed - HIV Clinical Trials

Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings

PLUS
Start date: August 1, 2013
Phase: N/A
Study type: Interventional

Alcohol use is increasingly recognized as a key factor in morbidity and mortality among HIV-positive individuals and represents an important public health concern, given its associations with medication non-adherence, increases in viral load, poor immunologic outcomes (lower cluster of differentiation 4, or CD4, counts), drug resistance, lower health care utilization, comorbidities (HIV/viral hepatitis coinfection), and poor health outcomes overall. Adherence to HIV medications has a double public health benefit, both in terms of slowing disease progression and improving health outcomes among HIV-positive individuals and in helping to curb the sexual transmission of HIV. The objective of this study is to implement a multisite comparative effectiveness trial in real-world clinical settings with three intensities of treatment to test the clinical and cost effectiveness of an efficacious, theory-based behavioral intervention (PLUS) in improving adherence to antiretroviral therapy (ART) and alcohol-related outcomes among HIV-positive individuals who drink alcohol at harmful or hazardous levels. The study is being conducted in collaboration between the Center for HIV Educational Studies and Training (CHEST) at Hunter College at the City University of New York (CUNY) and the Spencer Cox Center for Health at the Institute for Advanced Medicine, Mount Sinai Health System.

NCT ID: NCT02387489 Completed - Alcohol Consumption Clinical Trials

A Clinical Trial of SBIRT Services in School-based Health Centers

Start date: October 2, 2015
Phase: N/A
Study type: Interventional

The purpose of the study is to examine the comparative effectiveness of a computerized brief intervention vs. an in-person brief intervention delivered by a nurse in reducing marijuana, alcohol, and sex risk behaviors in adolescents receiving services in school-based health centers.

NCT ID: NCT02384278 Completed - Clinical trials for Alcohol Use Disorders

Internet Based Cognitive Behavior Treatment for Alcohol Problems

ICBT-AP
Start date: March 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether internet based cognitive behavior therapy might be effective in the treatment of alcohol problems.

NCT ID: NCT02380950 Completed - Bariatric Surgery Clinical Trials

Effect of Moderate Alcohol Consumption to Cognitive Functioning After Roux-en Y Gastric Bypass

Start date: June 2013
Phase: N/A
Study type: Interventional

Objectives: Alcohol metabolism is changed in gastric bypass patients, leading to faster resorption and higher alcohol peak concentrations in blood. Because of stronger alcohol effects after gastric bypass we suggest that also general cognitive function is stronger impaired. Materials and Methods: We included 28 females (12 gastric bypass patients, 8 obese and 8 normal weight subjects) in the study. Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser "Dräger Alcotest 7510".

NCT ID: NCT02378181 Completed - Drug Use Clinical Trials

Testing the Effectiveness of a Graphic Novel Health Education Curriculum for Patients With Addiction

Start date: August 16, 2016
Phase: N/A
Study type: Interventional

This study deploys a strategy to develop and evaluate a training-efficient, multimedia patient-centered Health Education Toolkit to promote shared decision making between counselors and patients. An existing evidence-based toolkit intervention will be adapted and redesigned by a patient and provider team into an engaging, narrative graphic novel curriculum useful in group and individual counseling. The proven behavioral interventions will be augmented with health education material focused on medication assisted treatment (MAT). We will assess feasibility and acceptability, and pilot test whether exposure to the Toolkit (TK) can shared decision making conversations, reduce substance use, and increase engagement with MAT.

NCT ID: NCT02377726 Completed - Clinical trials for Alcohol Use Disorder

Anonymous Treatment on the Internet for Alcohol Dependence: A Randomised, Controlled Trial

Start date: April 1, 2015
Phase: N/A
Study type: Interventional

Internet based self help program with or without support of a counselor is tested among anonymous Internet help seekers at an open access website.

NCT ID: NCT02364947 Completed - Alcohol Dependence Clinical Trials

A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)

Start date: February 9, 2015
Phase: Phase 3
Study type: Interventional

The efficacy, safety, and dose-response of nalmefene hydrochloride at 10 mg and 20 mg in patients with alcohol dependence will be evaluated in a multicenter, randomized, double-blind, placebo-controlled, 3-parallel-group comparative trial. The superiority of nalmefene hydrochloride at 20 mg to placebo will be verified in terms of reduction of alcohol consumption.